Medlab Clinical receives preliminary results from NanoStat™ trial

Medlab Clinical Ltd (ASX:MDC) has received and analysed the results of the NanoStat™ trial from Zenith in New Zealand. 

NanoStat is an investigative new sub-micron spray delivering a dosage of Atorvastatin in four pumps applied to the oro-buccal membrane (skin inside the mouth).

Atorvastatin is a statin medication used to lower cholesterol and was selected as it had specific comparative benefits when being tested in Medlab’s drug delivery platform (mouth spray).

Atorvastatin is predominantly provided to patients in tablet form.

Medlab aims to deliver medicinal cannabis using this drug delivery platform.

READ: Medlab outlines business development objectives at open day

Medlab’s CEO Dr Sean Hall said: “For those who recall why we undertook NanoCelle™ work with Atorvastatin, Atorvastatin had inherent properties that would test the NanoCelle™ capabilities beyond most generic drugs and our cannabis programs.

“These results further show the potential and widespread capabilities of

... read more at: https://www.proactiveinvestors.com.au/companies/news/212190/medlab-clinical-receives-preliminary-results-from-nanostat-trial-212190.html

by